BIOPHARMA CREDIT DL -01
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. The company debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. BioPharma Credit PLC was incorporated in 2016 and is based in Leeds, the United Kingdom.
Market Cap & Net Worth: BIOPHARMA CREDIT DL -01 (B3P)
BIOPHARMA CREDIT DL -01 (F:B3P) has a market capitalization of $7.54K (€7.34K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #7857 globally and #835 in its home market, demonstrating a 2.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOPHARMA CREDIT DL -01's stock price €0.81 by its total outstanding shares 9066 (9.07K).
BIOPHARMA CREDIT DL -01 Market Cap History: 2021 to 2026
BIOPHARMA CREDIT DL -01's market capitalization history from 2021 to 2026. Data shows growth from $7.01K to $7.54K (2.21% CAGR).
BIOPHARMA CREDIT DL -01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOPHARMA CREDIT DL -01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of B3P by Market Capitalization
Companies near BIOPHARMA CREDIT DL -01 in the global market cap rankings as of March 19, 2026.
Key companies related to BIOPHARMA CREDIT DL -01 by market ranking:
- Arcadyan Technology Corp (TW:3596): Ranked #7848 globally with a market cap of $879.84 Million USD ( NT$29.11 Billion TWD).
- Qingdao Gon Technology Co Ltd (SHE:002768): Ranked #7849 globally with a market cap of $879.70 Million USD ( CN¥6.45 Billion CNY).
- BioPharma Credit PLC (PINK:BOPCF): Ranked #7858 globally with a market cap of $877.80 Million USD.
- UNITIL Corporation (NYSE:UTL): Ranked #7859 globally with a market cap of $877.29 Million USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #7848 | Arcadyan Technology Corp | TW:3596 | $879.84 Million | NT$201.50 |
| #7849 | Qingdao Gon Technology Co Ltd | SHE:002768 | $879.70 Million | CN¥51.78 |
| #7858 | BioPharma Credit PLC | PINK:BOPCF | $877.80 Million | $0.88 |
| #7859 | UNITIL Corporation | NYSE:UTL | $877.29 Million | $51.86 |
BIOPHARMA CREDIT DL -01 Historical Marketcap From 2021 to 2026
Between 2021 and today, BIOPHARMA CREDIT DL -01's market cap moved from $7.01K to $ 7.54K, with a yearly change of 2.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.54K | +1.89% |
| 2025 | €7.40K | +5.30% |
| 2024 | €7.03K | +11.79% |
| 2023 | €6.29K | -13.96% |
| 2022 | €7.31K | +4.25% |
| 2021 | €7.01K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BIOPHARMA CREDIT DL -01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.54K USD |
| MoneyControl | $7.54K USD |
| MarketWatch | $7.54K USD |
| marketcap.company | $7.54K USD |
| Reuters | $7.54K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.